Correlation of the transcription factors IRF4 and BACH2 with the abnormal NFATC1 expression in T cells from chronic myeloid leukemia patients

References

• Chopra R, Pu QQ, Elefanty AG. Biology of BCR-ABL. Blood Rev. 1999;13(4):211–229.
   PubMed Web of Science ®Google Scholar
• Druker BJ. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med. 2001;344(14):1038–1042.
   PubMed Web of Science ®Google Scholar
• Marin D, Milojkovic D, Olavarria E, et al. European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. Blood. 2008;112(12):4437–4444.
   PubMed Web of Science ®Google Scholar
• Jangamreddy JR, Panigrahi S, Lotfi K, et al. Mapping of apoptin-interaction with BCR-ABL1, and development of apoptin-based targeted therapy. Oncotarget. 2014;5(16):7198–7211.
   PubMedGoogle Scholar
• Liu Z, Shi Y, Yan Z, et al. Impact of anemia on the outcomes of chronic phase chronic myeloid leukemia in TKI era. Hematology. 2020;25(1):181–185.
   PubMed Web of Science ®Google Scholar
• Hehlmann R, Hochhous A, Baccarani M, et al. Chronic myeloid leukaemia. Lancet. 2007;370(9584):342–350.
   PubMed Web of Science ®Google Scholar
• Xu L, Chen H, Chen J, et al. The consensus on indications, conditioning regimen, and donor selection of allogeneic hematopoietic cell transplantation for hematological diseases in China-recommendations from the Chinese Society of Hematology. J Hematol Oncol. 2018;11(1):33.
   PubMedGoogle Scholar
• Tumeh PC, Harview CL, Yearley JH, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515(7528):568–571.
   PubMed Web of Science ®Google Scholar
• Brudno JN, Somerville RPT, Shi V, et al. Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease. J Clin Oncol. 2016;34(10):1112–1121.
   PubMed Web of Science ®Google Scholar
• Wang H, Kaur G, Sankin AI, et al. Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies. J Hematol Oncol. 2019;12:59.
   PubMed Web of Science ®Google Scholar
• Zhao JJ, Song YP, Liu DL. Clinical trials of dual-target CAR T cells, donor-derived CAR T cells, and universal CAR T cells for acute lymphoid leukemia. J Hematol Oncol. 2019;12:17.
   PubMed Web of Science ®Google Scholar
• Zhao Q. Novel chimeric antigen receptor T cells based on T-cell receptor-like antibodies. Blood Sci. 2019;1(2):144–147.
   PubMedGoogle Scholar
• Zhao R, Cui Y, Li S, et al. Current status and hurdles for CAR-T cell immune therapy. Blood Sci. 2019;1(2):148–155.
   PubMedGoogle Scholar
• Taefehshokr N, Baradaran B, Baghbanzadeh A, et al. Promising approaches in cancer immunotherapy. Immunobiology. 2020;225(2):151875.
   PubMed Web of Science ®Google Scholar
• Zhang H, Zhao P, Huang H. Engineering better chimeric antigen receptor T cells. Exp Hematol Oncol. 2020;9(1):34.
   PubMed Web of Science ®Google Scholar
• Li YQ, Yang LJ, Chen SH, et al. T cell receptor V beta repertoire usage and clonal expansion of T cells in chronic myelogenous leukemia. Chin Med J. 2004;117(6):840–843.
   PubMed Web of Science ®Google Scholar
• Rohon P, Porkka K, Mustjoki S. Immunoprofiling of patients with chronic myeloid leukemia at diagnosis and during tyrosine kinase inhibitor therapy. Eur J Haematol. 2010;85(5):387–398.
   PubMed Web of Science ®Google Scholar
• Zha X, Chen S, Yang L, et al. Characterization of the CDR3 structure of the Vbeta21T cell clone in patients with P210(BCR-ABL)-positive chronic myeloid leukemia and B-cell acute lymphoblastic leukemia. Hum Immunol. 2011;72(10):798–804.
   PubMed Web of Science ®Google Scholar
• Yao DL, Xu L, Tan JX, et al. Re-balance of memory T cell subsets in peripheral blood from patients with CML after TKI treatment. Oncotarget. 2017;8(47):81852–81859.
   PubMedGoogle Scholar
• Li YQ, Geng SX, Yin QS, et al. Decreased level of recent thymic emigrants in CD4+  and CD8+ T cells from CML patients. J Transl Med. 2010;8:47.
   PubMed Web of Science ®Google Scholar
• Chen SH, Zha XF, Shi L, et al. Upregulated TCR zeta improves cytokine secretion in T cells from patients with AML. J Hematol Oncol. 2015;8:72.
   PubMed Web of Science ®Google Scholar
• Xu L, Lu YH, Lai J, et al. Characteristics of the TCR V beta repertoire in imatinib-resistant chronic myeloid leukemia patients with ABL mutations. Sci China-Life Sci. 2015;58(12):1276–1281.
   PubMed Web of Science ®Google Scholar
• Zha XF, Xu L, Chen SH, et al. Generation of V alpha 13/beta 21(+)T cell specific target CML cells by TCR gene transfer. Oncotarget. 2016;7(51):84246–84257.
   PubMedGoogle Scholar
• Gao R, Zhang Y, Zeng C, et al. The role of NFAT in the pathogenesis and targeted therapy of hematological malignancies. Eur J Pharmacol. 2022;921:174889.
   PubMed Web of Science ®Google Scholar
• Hogan PG. Calcium-NFAT transcriptional signalling in T cell activation and T cell exhaustion. Cell Calcium. 2017;63:66–69.
   PubMed Web of Science ®Google Scholar
• Schietinger A, Greenberg PD. Tolerance and exhaustion: defining mechanisms of T cell dysfunction. Trends Immunol. 2014;35(2):51–60.
   PubMed Web of Science ®Google Scholar
• Martinez GJ, Pereira RM, Äijö T, et al. The transcription factor NFAT promotes exhaustion of activated CD8+ T cells. Immunity. 2015;42(2):265–278.
   PubMed Web of Science ®Google Scholar
• Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–2405.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Xu L, Chen S, et al. Identification of TCR V11-2-D1-J1-1T cell clone specific for WT1 peptides using high-throughput TCR gene sequencing. Biomark Res. 2019;7:12.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wu J, Zeng C, et al. The role of NFAT2/miR-20a-5p signaling pathway in the regulation of CD8 naïve T cells activation and differentiation. Immunobiology. 2021;226(4):152111.
   PubMed Web of Science ®Google Scholar
• Wu Y, Hu Y, Yu X, et al. TAL1 mediates imatinib-induced CML cell apoptosis via the PTEN/PI3 K/AKT pathway. Biochem Biophys Res Commun. 2019;519(2):234–239.
   PubMed Web of Science ®Google Scholar
• Tsukumo S-i, Unno M, Muto A, et al. Bach2 maintains T cells in a naive state by suppressing effector memory-related genes. Proc Natl Acad Sci U S A. 2013;110(26):10735–10740.
   PubMed Web of Science ®Google Scholar
• Roychoudhuri R, Clever D, Li P, et al. BACH2 regulates CD8(+) T cell differentiation by controlling access of AP-1 factors to enhancers. Nat Immunol. 2016;17(7):851–860.
   PubMed Web of Science ®Google Scholar
• Yao C, Lou G, Sun H-W, et al. BACH2 enforces the transcriptional and epigenetic programs of stem-like CD8T cells. Nat Immunol. 2021;22(3):370–380.
   PubMed Web of Science ®Google Scholar
• Raczkowski F, Ritter J, Heesch K, et al. The transcription factor interferon regulatory factor 4 is required for the generation of protective effector CD8+ T cells. Proc Natl Acad Sci U S A. 2013;110(37):15019–15024.
   PubMed Web of Science ®Google Scholar
• Harberts A, Schmidt C, Schmid J, et al. Interferon regulatory factor 4 controls effector functions of CD8 memory T cells. Proc Natl Acad Sci U S A. 2021;118(16):e2014553118.
   PubMed Web of Science ®Google Scholar
• Peng SL, Gerth AJ, Ranger AM, et al. NFATc1 and NFATc2 together control both T and B cell activation and differentiation. Immunity. 2001;14(1):13–20.
   PubMed Web of Science ®Google Scholar
• Macian F. NFAT proteins: key regulators of T-cell development and function. Nat Rev Immunol. 2005;5(6):472–484.
   PubMed Web of Science ®Google Scholar
• Koch S, Reppert S, Finotto S. NFATc1 deletion in T lymphocytes inhibits the allergic trait in a murine model of asthma. Clin Exp Allergy. 2015;45(8):1356–1366.
   PubMed Web of Science ®Google Scholar
• Klein-Hessling S, Rudolf R, Muhammad K, et al. A threshold level of NFATc1 activity facilitates thymocyte differentiation and opposes notch-driven leukaemia development. Nat Commun. 2016;7:11841.
   PubMed Web of Science ®Google Scholar
• Li Y, Geng S, Du X, et al. Restricted TRBV repertoire in CD4 + and CD8+ T-cell subsets from CML patients. Hematology. 2011;16(1):43–49.
   PubMed Web of Science ®Google Scholar
• Zha X, Chen S, Yang L, et al. Upregulated TCRζ enhances interleukin-2 production in T-cells from patients with CML. DNA Cell Biol. 2012;31(11):1628–1635.
   PubMed Web of Science ®Google Scholar
• Zha X, Yan X, Shen Q, et al. Alternative expression of TCRζ related genes in patients with chronic myeloid leukemia. J Hematol Oncol. 2012;5:74.
   PubMed Web of Science ®Google Scholar
• Martinez GJ, Pereira RM, Aijo T, et al. The transcription factor NFAT promotes exhaustion of activated CD8(+) T cells. Immunity. 2015;42(2):265–278.
   PubMed Web of Science ®Google Scholar
• Klein-Hessling S, Muhammad K, Klein M, et al. NFATc1 controls the cytotoxicity of CD8(+) T cells. Nat Commun. 2017;8:511.
   PubMed Web of Science ®Google Scholar
• Xu TH, Keller A, Martinez GJ. NFAT1 and NFAT2 differentially regulate CTL differentiation upon acute viral infection. Front Immunol. 2019;10:184.
   PubMed Web of Science ®Google Scholar
• Kiani A, Viola JP, Lichtman AH, et al. Down-regulation of IL-4 gene transcription and control of Th2 cell differentiation by a mechanism involving NFAT1. Immunity. 1997;7(6):849–860.
   PubMed Web of Science ®Google Scholar
• Porter CM, Clipstone NA. Sustained NFAT signaling promotes a Th1-like pattern of gene expression in primary murine CD4(+) T cells. J Immunol. 2002;168(10):4936–4945.
   PubMed Web of Science ®Google Scholar
• Rengarajan J, Tang B, Glimcher LH. NFATc2 and NFATc3 regulate T(H)2 differentiation and modulate TCR-responsiveness of naive T-H cells. Nat Immunol. 2002;3(1):48–54.
   PubMed Web of Science ®Google Scholar
• Huber M, Lohoff M. IRF4 at the crossroads of effector T-cell fate decision. Eur J Immunol. 2014;44(7):1886–1895.
   PubMed Web of Science ®Google Scholar
• Nam S, Lim JS. Essential role of interferon regulatory factor 4 (IRF4) in immune cell development. Arch Pharm Res. 2016;39(11):1548–1555.
   PubMed Web of Science ®Google Scholar
• Yao D, Xu L, Tan J, et al. Re-balance of memory T cell subsets in peripheral blood from patients with CML after TKI treatment. Oncotarget. 2017;8(47):81852–81859.
   PubMedGoogle Scholar